Single User License
INR 134840
Site License
INR 269680
Corporate User License
INR 404520

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Ventilator Associated Pneumonia (VAP)-Pipeline Review, H1 2015

Ventilator Associated Pneumonia (VAP)-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Ventilator Associated Pneumonia (VAP)-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Ventilator Associated Pneumonia (VAP)-Pipeline Review, H1 2015', provides an overview of the Ventilator Associated Pneumonia (VAP)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Ventilator Associated Pneumonia (VAP), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ventilator Associated Pneumonia (VAP) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Ventilator Associated Pneumonia (VAP)

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Ventilator Associated Pneumonia (VAP) and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Ventilator Associated Pneumonia (VAP) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Ventilator Associated Pneumonia (VAP) pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Ventilator Associated Pneumonia (VAP)

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Ventilator Associated Pneumonia (VAP) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Ventilator Associated Pneumonia (VAP) Overview 8

Therapeutics Development 9

Pipeline Products for Ventilator Associated Pneumonia (VAP)-Overview 9

Pipeline Products for Ventilator Associated Pneumonia (VAP)-Comparative Analysis 10

Ventilator Associated Pneumonia (VAP)-Therapeutics under Development by Companies 11

Ventilator Associated Pneumonia (VAP)-Therapeutics under Investigation by Universities/Institutes 13

Ventilator Associated Pneumonia (VAP)-Pipeline Products Glance 14

Late Stage Products 14

Clinical Stage Products 15

Early Stage Products 16

Unknown Stage Products 17

Ventilator Associated Pneumonia (VAP)-Products under Development by Companies 18

Ventilator Associated Pneumonia (VAP)-Products under Investigation by Universities/Institutes 19

Ventilator Associated Pneumonia (VAP)-Companies Involved in Therapeutics Development 20

Adenium Biotech ApS 20

AstraZeneca PLC 21

Cardeas Pharma Corp. 22

Cubist Pharmaceuticals, Inc. 23

Dong-A Socio Group 24

F. Hoffmann-La Roche Ltd. 25

KaloBios Pharmaceuticals, Inc. 26

Meiji Seika Pharma Co., Ltd. 27

Nabriva Therapeutics AG 28

Paratek Pharmaceuticals, Inc. 29

Savara Inc. 30

Serendex Pharmaceuticals A/S 31

Tetraphase Pharmaceuticals Inc. 32

Ventilator Associated Pneumonia (VAP)-Therapeutics Assessment 33

Assessment by Monotherapy Products 33

Assessment by Combination Products 34

Assessment by Target 35

Assessment by Mechanism of Action 37

Assessment by Route of Administration 39

Assessment by Molecule Type 41

Drug Profiles 43

(amikacin + fosfomycin)-Drug Profile 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

(ceftazidime + avibactam)-Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

(ceftolozane sulfate + tazobactam sodium)-Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

AA-139-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

arbekacin-Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

BC-3781-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

eravacycline-Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

fosfomycin-Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

KB-001A-Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

MEDI-4893-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

molgramostim-Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

Nu-2-Drug Profile 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

pseudomonas aeruginosa vaccine-Drug Profile 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

pseudomonas and VAP conjugate vaccine-Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

Qn-2251-Drug Profile 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

RG-7929-Drug Profile 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

Small Molecules for Infectious Diseases-Drug Profile 67

Product Description 67

Mechanism of Action 67

R&D Progress 67

tedizolid phosphate-Drug Profile 68

Product Description 68

Mechanism of Action 68

R&D Progress 68

vancomycin hydrochloride-Drug Profile 71

Product Description 71

Mechanism of Action 71

R&D Progress 71

Ventilator Associated Pneumonia (VAP)-Recent Pipeline Updates 73

Ventilator Associated Pneumonia (VAP)-Dormant Projects 93

Ventilator Associated Pneumonia (VAP)-Discontinued Products 94

Ventilator Associated Pneumonia (VAP)-Product Development Milestones 95

Featured News & Press Releases 95

May 07, 2013: Cubist's Late-stage Antibiotic Candidate CXA-201 Receives FDA Fast Track Designation 95

Appendix 96

Methodology 96

Coverage 96

Secondary Research 96

Primary Research 96

Expert Panel Validation 96

Contact Us 97

Disclaimer 97

List of Tables

Number of Products under Development for Ventilator Associated Pneumonia (VAP), H1 2015 9

Number of Products under Development for Ventilator Associated Pneumonia (VAP)-Comparative Analysis, H1 2015 10

Number of Products under Development by Companies, H1 2015 12

Number of Products under Investigation by Universities/Institutes, H1 2015 13

Comparative Analysis by Late Stage Development, H1 2015 14

Comparative Analysis by Clinical Stage Development, H1 2015 15

Comparative Analysis by Early Stage Development, H1 2015 16

Comparative Analysis by Unknown Stage Development, H1 2015 17

Products under Development by Companies, H1 2015 18

Products under Investigation by Universities/Institutes, H1 2015 19

Ventilator Associated Pneumonia (VAP)-Pipeline by Adenium Biotech ApS, H1 2015 20

Ventilator Associated Pneumonia (VAP)-Pipeline by AstraZeneca PLC, H1 2015 21

Ventilator Associated Pneumonia (VAP)-Pipeline by Cardeas Pharma Corp., H1 2015 22

Ventilator Associated Pneumonia (VAP)-Pipeline by Cubist Pharmaceuticals, Inc., H1 2015 23

Ventilator Associated Pneumonia (VAP)-Pipeline by Dong-A Socio Group, H1 2015 24

Ventilator Associated Pneumonia (VAP)-Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 25

Ventilator Associated Pneumonia (VAP)-Pipeline by KaloBios Pharmaceuticals, Inc., H1 2015 26

Ventilator Associated Pneumonia (VAP)-Pipeline by Meiji Seika Pharma Co., Ltd., H1 2015 27

Ventilator Associated Pneumonia (VAP)-Pipeline by Nabriva Therapeutics AG, H1 2015 28

Ventilator Associated Pneumonia (VAP)-Pipeline by Paratek Pharmaceuticals, Inc., H1 2015 29

Ventilator Associated Pneumonia (VAP)-Pipeline by Savara Inc., H1 2015 30

Ventilator Associated Pneumonia (VAP)-Pipeline by Serendex Pharmaceuticals A/S, H1 2015 31

Ventilator Associated Pneumonia (VAP)-Pipeline by Tetraphase Pharmaceuticals Inc., H1 2015 32

Assessment by Monotherapy Products, H1 2015 33

Assessment by Combination Products, H1 2015 34

Number of Products by Stage and Target, H1 2015 36

Number of Products by Stage and Mechanism of Action, H1 2015 38

Number of Products by Stage and Route of Administration, H1 2015 40

Number of Products by Stage and Molecule Type, H1 2015 42

Ventilator Associated Pneumonia (VAP) Therapeutics-Recent Pipeline Updates, H1 2015 73

Ventilator Associated Pneumonia (VAP)-Dormant Projects, H1 2015 93

Ventilator Associated Pneumonia (VAP)-Discontinued Products, H1 2015 94

List of Figures

Number of Products under Development for Ventilator Associated Pneumonia (VAP), H1 2015 9

Number of Products under Development for Ventilator Associated Pneumonia (VAP)-Comparative Analysis, H1 2015 10

Number of Products under Development by Companies, H1 2015 11

Comparative Analysis by Clinical Stage Development, H1 2015 15

Comparative Analysis by Early Stage Products, H1 2015 16

Assessment by Monotherapy Products, H1 2015 33

Assessment by Combination Products, H1 2015 34

Number of Products by Top 10 Targets, H1 2015 35

Number of Products by Stage and Top 10 Targets, H1 2015 35

Number of Products by Top 10 Mechanism of Actions, H1 2015 37

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 37

Number of Products by Top 10 Routes of Administration, H1 2015 39

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 40

Number of Products by Top 10 Molecule Types, H1 2015 41

Number of Products by Stage and Top 10 Molecule Types, H1 2015 42

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Adenium Biotech ApS

AstraZeneca PLC

Cardeas Pharma Corp.

Cubist Pharmaceuticals, Inc.

Dong-A Socio Group

F. Hoffmann-La Roche Ltd.

KaloBios Pharmaceuticals, Inc.

Meiji Seika Pharma Co., Ltd.

Nabriva Therapeutics AG

Paratek Pharmaceuticals, Inc.

Savara Inc.

Serendex Pharmaceuticals A/S

Tetraphase Pharmaceuticals Inc.

Ventilator Associated Pneumonia (VAP) Therapeutic Products under Development, Key Players in Ventilator Associated Pneumonia (VAP) Therapeutics, Ventilator Associated Pneumonia (VAP) Pipeline Overview, Ventilator Associated Pneumonia (VAP) Pipeline, Ventilator Associated Pneumonia (VAP) Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com